Friday, July 17, 2026

pharma · Diabetes Mellitus · Hemophilia A

Takeda

Takeda is a pharma organization headquartered in Cambridge, USA. Primary therapeutic focus areas include Diabetes Mellitus, Hemophilia A, Crohn's Disease, Hypertension, Type 2 Diabetes Mellitus. NovaPharmaNews links 1179

Cambridge, USA HQ
1993 Founded
1,617 Employees
NMPA registrant Type
Company details
Status
Public
HQ
Cambridge, USA
Founded
1993
Employees
1,617
Programs
1179
Drugs
283
Patents
1436
Clinical program

blood sampling (alpha-Galactosidase & LysoGb3)

Unknown · other · Fabry Disease

blood sampling (alpha-Galactosidase & LysoGb3) for Fabry Disease is a Unknown program (other) at Takeda with 1 ClinicalTrials.gov record(s).

← All Takeda projects Unknown other active

Internal code FAPREV-HCM

Full intelligence profile for this program is being prepared.

At a glance

Sponsor
Takeda
Phase
Unknown
Modality
other
Indication
Fabry Disease
Status
active
Trials
1